"目录号: HY-13662B
Membrane Transporter/Ion Channel-
(R)-Lansoprazole是质子泵抑制剂，能抑制胃酸生成。
相关产品
TAK-438-Omeprazole-Pantoprazole sodium-Lansoprazole-Zinc Pyrithione-AZD0865-Ilaprazole-Esomeprazole Magnesium trihydrate-Bamaquimast-Rabeprazole sodium-Soraprazan-Chebulinic acid-Picoprazole-SKF96067-Tenatoprazole sodium-
生物活性
Description
(R)-Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid.Target: Proton PumpLansoprazole sodium is sodium salt form of lansoprazole, lansoprazole, a substituted benzimidizole proton pump inhibitor, on pharmacokinetics and metabolism of theophylline has been studied in healthy adults given oral lansoprazole 30 mg once daily for 11 days. On Days 4 and 11 of 300 mg aminophylline was simultaneously administered orally and blood samples for theophylline analysis were taken over 24 h [1]. Patients in the lansoprazole group were significantly less likely to have a recurrence of ulcer complications than patients in the placebo group (P=0.008). There was no significant difference in mortality between the two groups [2]. lansoprazole (AG-1749) and omeprazole, were found to have significant activities against this organism. The activity of lansoprazole was comparable to that of bismuth citrate, with MICs ranging from 3.13 to 12.5 micrograms/ml, and fourfold more potent than that of omeprazole [3]. �
Clinical Trial
Takeda
Gastroesophageal Reflux Disease
July 2012
Phase 2
Takeda
Gastroesophageal Reflux Disease-Erosive Esophagitis-Heartburn
February 2014
Phase 1
Takeda
Bioavailability
February 2014
Phase 1
Takeda
Pediatric Gastroesophageal Reflux Disease
February 2016
Phase 1
Takeda
Barrett's Esophagus
July 2014
Phase 2
Takeda
Gastroesophageal Reflux
November 2015
Phase 2
Indiana University
Laryngopharyngeal Reflux
March 2011
Ramathibodi Hospital
H Pylori Eradication
January 1, 2017
Phase 4
Takeda
Gastroesophageal Reflux Disease
March 2015
Phase 4
Takeda
Gastroesophageal Reflux Disease-Erosive Esophagitis
July 2012
Phase 2
Takeda
Erosive Esophagitis
November 2015
Phase 2
Takeda
Gastroesophageal Reflux Disease
January 2006
Phase 3
Kaohsiung Medical University
Helicobacter Pylori Infection
January 2015
Phase 4
Takeda
Gastroesophageal Reflux
May 2009
Phase 1
Takeda
Heartburn-Gastroesophageal Reflux Disease
December 31, 2016
Phase 3
Advanced Center for Specialty Care-Takeda
Laryngopharyngeal Reflux-Hypertrophy of Lingual Tonsil
June 2011
Phase 4
American University of Beirut Medical Center-Takeda
GERD-Proton Pump Inhibitor
February 27, 2017
Phase 4
Kaohsiung Medical University Chung-Ho Memorial Hospital
Gastroesophageal Reflux Disease
April 1, 2014
Phase 4
Takeda
Gastroesophageal Reflux
February 2009
Phase 3
Takeda
Esophagitis, Reflux-Esophagitis, Peptic
January 2006
Phase 3
Takeda
Esophagitis, Reflux-Esophagitis, Peptic
January 2006
Phase 3
Takeda
Gastroesophageal Reflux Disease
December 2005
Phase 3
Takeda
Gastroesophageal Reflux Disease
December 2005
Phase 3
Takeda
Gastroesophageal Reflux Disease
June 2006
Phase 3
Takeda
Gastroesophageal Reflux
March 2010
Phase 1
Takeda
Homeostasis-Bone and Bones
January 2011
Phase 1
Takeda
Erosive Esophagitis
December 31, 2016
Phase 3
Takeda
Healthy Volunteers
April 24, 2017
Phase 1
First Affiliated Hospital of Zhejiang University-Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Effect of Drugs-Safety Issues
May 5, 2017
Phase 1
Takeda
Esophagitis, Reflux-Esophagitis, Peptic
December 2005
Phase 3
Takeda
Esophagitis, Reflux-Esophagitis, Peptic
December 2005
Phase 3
Takeda
Esophagitis, Reflux-Esophagitis, Peptic
May 2006
Phase 3
National Cheng-Kung University Hospital
Gastroesophageal Reflux Disease
October 2015
Phase 4
Takeda
Gastroesophageal Reflux
March 2008
Phase 3
University of North Carolina, Chapel Hill
Heartburn-Gastroesophageal Reflux Disease
June 2010
Phase 1
First Affiliated Hospital of Zhejiang University-Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Safety Issues
January 2017
Phase 1
Takeda
Healthy
December 2009
Phase 1
Northwestern University-Washington University School of Medicine-Vanderbilt University
Gastro Esophageal Reflux
July 1, 2017
Early Phase 1
University of Washington-Takeda Pharmaceuticals North America, Inc.
Laryngo-pharyngeal Reflux
May 2011
Mayo Clinic
Inflammation-Barrett's Esophagus
March 2010
Phase 4
Mayo Clinic
Gastroesophageal Reflux Disease-Eosinophilic Esophagitis-Dysphagia
March 2012
Phase 1-Phase 2
Soonchunhyang University Hospital
Nonerosive Reflux Disease
December 2014
CJ HealthCare Corporation
Healthy
May 13, 2015
Phase 1
M.D. Anderson Cancer Center-TAP Pharmaceutical Products Inc.
Head and Neck Cancer-Oropharyngeal Cancer-Gastroesophageal Reflux Disease
November 2012
View MoreCollapse
References
